Our CAR-T therapy targeting five common membrane protein cancer antigens—EphB4, CLDN1, LAT1, ROBO1, and GPC3—may be effective against many solid tumors, including childhood cancers. Here, EPHB4 is linked to childhood malignant neoplasm.